论文部分内容阅读
目的:采用对照分析,对比舒利迭、信必可联合噻托溴铵治疗中重度慢性阻塞性肺疾病(COPD)稳定期的疗效。方法:从2015年2月~2016年8月,入选对象120例,采用随机数字表达法分组,舒利迭组、信必可组、联合A组、联合B组各30例,舒利迭组采用舒利迭治疗,信必可组采用信必可治疗,联合A组舒利迭联合噻托溴铵,联合B组信必可联合噻托溴铵,对比治疗前后各组效果。结果:治疗后,组内对比,舒利迭组、信必可组、联合A组、联合B组的FENO、Raw、CAT评分低于治疗前,组间对比联合A组、联合B组低于舒利迭组与信必可组,组内对比四组FEV1/FVC、6-MWD高于治疗前,组间对比,联合A组、联合B组高于舒利迭组与信必可组,差异有统计学意义(P<0.05)。组间对比,联合A组、联合B组各指标对比差异无统计学意义(P>0.05),舒利迭组、信必可组各指标对比差异无统计学意义(P>0.05)。结论:联合噻托溴铵治疗中重度COPD稳定期有助于肺功能的恢复,减轻气道阻力,控制炎症反应,降低急性发作风险。
OBJECTIVE: To compare the efficacy of seretide and xinbide in combination with tiotropium in the treatment of stable chronic obstructive pulmonary disease (COPD). Methods: From February 2015 to August 2016, 120 patients were enrolled in this study. Random number expression was used to divide the patients. The patients in each group were treated with seretide, The use of seretide treatment, the letter will be treated with the letter will be treated with the combination of group A seretide combined with tiotropium, combined with the letter B group will be able to combine tiotropium, compared to the effect of each group before and after treatment. Results: After treatment, FENO, Raw, CAT scores of the group of seretide, the group of Xin Keke, the group of combined A and the group B were lower than those of the group A before treatment and the group B was lower than the group B Comparing with the group of Shuxudi and Xinbiku, the FEV1 / FVC and 6-MWD of the four groups were higher than those before treatment and group A Statistical significance (P <0.05). There was no significant difference in each index between group A and group B (P> 0.05). There was no significant difference between each group (P> 0.05). Conclusions: The combined treatment of tiotropium and stable COPD can help the recovery of lung function, reduce airway resistance, control inflammatory response and reduce the risk of acute exacerbation.